Ce bulletin du PNMVS est consacré à l’événement scientifique qui s’est déroulé à Rio de Janeiro du 24 au 27 juillet dernier : la 3^e conférence sur la pathogenèse et les traitements (3rd Conference on Pathogenesis and Treatment).

Dans le but d’être le plus exhaustif possible, nous vous proposons des abrégés de la conférence, classés selon la thématique abordée, et les rapports du Clinical Care Options

Toutefois, et compte tenu de l’abondance des informations, nous vous invitons à vous rendre directement sur le site du programme de la conférence.

• Grivel, J.-C. et autres
  Non-infectious X4 but not R5 HIV-1 virions inhibit humoral immune responses in human lymphoid tissue ex vivo.
  
  
• Olmos, M. et autres
  The gut is an HIV-1 reservoir regardless of plasma viral load level (pVL) in patients on and off HAART.
  
  
• Haas, D. et autres
  Immunogenetics and immune reconstitution during potent antiretroviral therapy: NWCS 233, an analysis of AACTG protocol A5001.
  
  
• Haddad, E. et autres
  Defective survival pathways in memory T cells during HIV infection.
  
  
• Foxall, R. et autres
  Comparison of HIV-specific CD4+ T cell responses in HIV1 and HIV2.
  
  
• Mavilio, D. et autres
  Dendritic cell and natural killer cell interactions in HIV-1 infected viremic individuals. 
  

• Thorne, C. et autres
  HIV-infected pregnant women and mother-to-child transmission in Europe: characteristics of the epidemics in Western, Central and Eastern Europe.
  
  
• Phanuphak, N. et autres
  Dendritic cell and natural killer cell interactions in HIV-1 infected viremic individuals.
  
  

• Jiang, S. et autres
  Small molecule HIV entry inhibitors targeting gp41.
  
  
• Van Lunzen, L. et autres
  Immune therapy of advanced HIV-1 infection by transduced autologous T helper cells expressing a peptide which inhibits viral entry. Results of a phase I pilot study.
  
  
• Smith, K. et autres
  Treatment with growth hormone leads to improvement in total and naïve CD4 lymphocyte recovery in HIV-infected subjects with incomplete immune reconstitution on HAART.
  
  
• McHale, M. et autres
  Overview of phase 1 and 2a safety and efficacy data of maraviroc (UK-427,857).
  
  
• Schuermann, D. et autres
  SCH 417690: antiviral activity of a potent new CCR5 receptor antagonist.
  

• Munerato, P. et autres
  Patterns of HIV-1 genotypic antiretroviral resistance in clinical practice: a survey of the Brazilian Network for Genotypic Resistance.
  
  
• Xing, H. et autres
  HIV-1 drug resistance in China: nation-wide survey and analysis of impacting factors in the national ARV treatment program.
  
  
• Price, H. et autres
  The presence of a single canonical NNRTI resistance mutation in naïve HIV-1 infected patients reduces the proportion achieving virological success when starting NNRTI-based regimens.
  
  
• Parisi, S.G. et autres
  HIV-proviral DNA and plasma-RNA sequencing for detection of drug resistance mutations in antiretroviral naive patients.
  
  
• McColl, D. et autres
  Lack of resistance to tenofovir at week 48 and impact of baseline resistance mutations on treatment response in study 934.
  
  
• Van Lunzen, L. et autres
  High rate of virological failure during once daily therapy with tenofovir + didanosine 250mg + efavirenz in antiretroviral naive patients – Results of the 12 week interim analysis of the TEDDI trial.
  

• Lafeuillade, A. et autres
  Investigating cellular antiretroviral resistance: preliminary results of the “ICARE” study.
  
  
• Pozniak, A.L. et autres
  Superior outcome for tenofovir DF (TDF), emtricitabine (FTC) and efavirenz (EFV) compared to fixed dose zidovudine/lamivudine (CBV) and EFV in antiretroviral naïve patients.
  
  
• McKinnon J.E. et autres
  The level of persistent viremia does not increase after simplification of maintenance antiretroviral therapy to lopinavir/ritonavir alone.
  
  
• Vernazza, P. et autres
  Viral suppression in CSF and genital tract in ritonavir-boosted "atazanavir only" maintenance therapy (ATARITMO-Study).
  
  
• Valdez H. et autres
  Tipranavir/ritonavir (TPV/r) 500 mg/200 mg BID drives week 24 viral load (VL) below 400 copies/mL when combined with a second active drug (T-20) in protease inhibitor experienced HIV+ patients.
  
  
• Awni, W. et autres
  Significantly reduced food effect and pharmacokinetic variability with a novel lopinavir/ritonavir tablet formulation.
  

• Frankel, F. et autres
  The L74V mutation in HIV-1 RT impairs unblocking of ZDV-terminated DNA primers and reduces synthesis of viral DNA in real-time PCRMuzammil, S. et autres
  Binding energetics analysis shows a unique response of tipranavir to HIV-1 protease mutations associated with drug resistance.
  
  
• Rosa Borges, A. et autres
  Multivalent compounds functionalized with the carbohydrate headgroups of immune cell-surface GSLs as inhibitors of HIV-1 infection.
  
  
• Coulombe, R. et autres
  Crystallographic study with BILR 355 BS, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) with a broad anti HIV-1 profile.
  
  
• Novel compounds that inhibit HIV replication by acting through inhibition of HIV rev function.
  

• Possible source of infection of "NYC Rapid Progressor" Identified.
  
  
• Screening for acute primary HIV infection in high-risk, resource-poor setting.
  
  
• Interpatient variability in CD4+ cell count response in patients with HIV suppression linked to T-Cell gene polymorphisms.
  
  
• NNRTI TMC120 nontoxic and effectively inhibits HIV-1 infection in cellular and cervical tissue models.
  
  
• Lopinavir/ritonavir-based regimen produces rapid viral load decrease in young children despite low plasma drug concentrations.
  
  
• Variable plasma drug levels in children receiving lopinavir/ritonavir.
  
  
• Mitochondrial toxicity associated with concurrent tenofovir/didanosine treatment may contribute to renal dysfunction.
  
  
• Factors associated with diabetes mellitus in D:A:D Study.
  
  
• Switch to atazanavir improves lipid profile in patients on HAART.
  
  Continued lamivudine monotherapy after treatment failure associated with fewer immunologic and clinical failures than full treatment interruption.
  
  HIV-1 disease, not HAART use, linked to bone demineralization.
  
  Elevated Incidence of Thyroid Disease Among Patients on HAART.
  
  48 weeks peginterferon alfa-2a/ribavirin treatment superior to 24 weeks for HIV/HCV genotype 2 or 3 coinfection.
  
  Switch from stavudine to tenofovir reverses lipid abnormalities, lipodystrophy.
  
  Metabolic syndrome more common in HIV-infected men than in uninfected men in MACS.